## **Core Concept**
The question revolves around the management of a pregnant woman with a history of embolism in the puerperium, likely referring to **puerperal venous thromboembolism (VTE)**. The condition suggests a high risk for recurrent thromboembolic events in future pregnancies. The management involves **antithrombotic prophylaxis** to prevent recurrence.

## **Why the Correct Answer is Right**
The correct approach for a pregnant woman with a history of venous thromboembolism, especially one that occurred in the puerperium, involves the use of **anticoagulants** throughout the pregnancy and postpartum period to minimize the risk of recurrence. **Low Molecular Weight Heparin (LMWH)** is commonly recommended for pregnant women due to its effectiveness and safety profile for both the mother and the fetus.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not specified, but if it involves **aspirin**, it's not sufficient for someone with a history of VTE. Aspirin has antiplatelet effects but does not provide adequate anticoagulation for preventing recurrent VTE.
- **Option B:** Similarly, not specified, but if it suggests **no treatment**, this is incorrect given the patient's history of VTE. Discontinuing anticoagulation in such high-risk patients would significantly increase the risk of another thromboembolic event.
- **Option C:** If this option suggests **warfarin**, it is generally avoided in pregnancy, especially during the first and third trimesters, due to its teratogenic effects and the risk of fetal bleeding.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that women with a history of VTE are at increased risk for recurrence during pregnancy and the postpartum period. **Risk stratification** is crucial, and **LMWH** is often the preferred anticoagulant for pregnant women due to its safety and efficacy.

## **Correct Answer: D. Low Molecular Weight Heparin.**